News 17/05/2022

Deenova Keeps Up its Competitive Streak in France with 2 New Tender Awards at Hazebrouck and Mantes-La-Jolie

MILAN–(BUSINESS WIRE)– Deenova today announced that it continued its last 2 years market dominance in France with another net new RESAH competitive award for its D3 ACCED mechatronic solutions at Centre Hospitalier Hazebrouck near Dunkerque. Separately, Deenova is pleased to simultaneously announce add-on sales of 4 ASTUS cabinets to existing Deenova customer Centre Hospitalier François Quesnay de Mantes-La-Jolie.

Loïc Bessin, Managing Director of Deenova in France stated: “Combining net new business awards at premier hospital groups like RESAH with Centre Hospitalier Hazebrouck, while at the same time earning the trust of additional add-on sales by previous Deenova customers such as Centre Hospitalier François Quesnay de Mantes-La-Jolie is self-evident proof of Deenova France maturity, showing a high level of continued satisfaction with our automation solutions amongst our existing customer base in France.”

Christophe JaffuelDeenova Chief Commercial Officer, added: “I am extremely pleased to continue to witness since 2019 the important and yearly contribution that RESAH ongoing awards means to Deenova in France, renewing its past commitment to Deenova well established mechatronic Unit-Dose solutions like D3 ACCED. I look forward to continuing the market leading cooperation with RESAH in the future.”

Centre Hospitalier Hazebrouck is a public health establishment located in the Lille Métropole healthcare area, and certified by the High Authority for Health in 2019. It assumes the functions of a local hospital for a population of approximately 124,000 inhabitants, with a capacity of 94 hospital beds, centered on medicine, surgery and gynecology-obstetrics, an Emergency Reception Service and a Home Hospitalization service. It also has an accommodation structure for the elderly (EHPAD) with 136 beds, a CSAPA (Centre for Care, Support and Prevention in Addictology) and 20 Aftercare and Rehabilitation beds. Patients benefit from consultations and expert advice as well as a high-quality technical platform with a medical imaging, 4 operating theaters, 3 birthing rooms, a pharmacy and sterilization units with 470 medical and non-medical staff.

Centre Hospitalier François Quesnay de Mantes-La-Jolie is a public health establishment opened in October 1997, bringing together all short-stay services (medicine, surgery, obstetrics), Aftercare and Rehabilitation (SSR), with 612-bed hospital in the Paris metropolitan area, and with a budget of 125 million euros and 175 doctors.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 03/05/2022

Deenova Launches First Ever, Pay-Per-Dose Unit Dose Pharmacy Automation Service in England

Milan, Italy (Deenova) – Today, Deenova announced that it is launching its innovative Pay-Per-Dose unit dose pharmacy automation service to the UK market for the first time. Deenova was the first company to bring a fully automated, closed-loop solution for the management of medication and medical supplies to the UK following a hugely successful pilot at University Hospitals Leicester. This newly designed Pay-Per-Dose solution is initially offered in late 2022 for the Greater London Metropolitan Area to both NHS and private hospitals. Deenova thus opens its market reach to short-term and easy-to-adopt contractual arrangements and flexibility in England´s Pharmacy Automation market.

Deenova is making the unit dose concept a reality in the UK. Its end-to-end pharmacy automation service not only personalises medicine dispensation and administration to individual patients, but enables closed-loop medication management; fully tracking and managing medicines from prescription, through to patient administration. This innovative approach promises to ease growing pressures on healthcare providers in the UK by increasing patient safety, reducing treatment dispensing errors and medicine waste, containing costs, and saving nurses’ and pharmacists’ time.

Gaspar G. De Viedma, Vice Chairman of the Board of Directors at Deenova stated: “I am very bullish about this exciting new venture, especially on the heels of our 15-year award from University Hospitals of Leicester NHS Trust in Europe´s second largest GDP healthcare market, and after the first ever successful unit dose implementation in the United Kingdom. The patient safety and economic advantages of Deenova´s unique closed-loop medication unit dose system were already clearly evidenced by the positive evaluation report issued by the East Midlands Academic Health Science Network (AHSN) following an 18-month evaluation of Deenova’s closed-loop solutions.”

The new pay-per-dose unit dose pharmacy automation is a full service, yet modular solution. It includes Deenova’s ORBIT Software for e-prescribing and micro-logistic management, all IT infrastructure hosting and integration with hospital Health Information Systems (HIS), its proprietary and award winning mechatronic devices for the production of unit doses, and the All-In-1 Station – a fully automated solution for the dispensation of personalised therapies. Deenova’s pay-per-dose service also includes staff to manage the full medication traceability process, as well all support functions such as training, maintenance, hot line support, analytics and reporting.

Deenova will officially launch its pay-per-dose unit dose pharmacy automation solution during the UK Clinical Pharmacy Congress at the lunch time symposia show, floor theatre, Friday 13 May at 1:00pm.

Christophe Jaffuel, Deenova´s Chief Commercial Officer, added: Deenova has been delivering end-to-end unit dose solutions across Europe for decades. I look forward to personally working with English hospitals in the Greater London Metropolitan Area, and with our newly appointed UK Commercial Director Andrew Lyon in making these extremely flexible and cost effective solutions a successful reality for Deenova.”

About Deenova

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.

Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

Deenova have been delivering unit dose solutions provided as a complete end-to-end service to hospitals across Europe for 18 years, with more than 70 projects to date – partnering with regional healthcare trusts to deliver results at scale.

News 31/03/2022

Marco D’Incà joins Deenova to support its unprecedented international growth and new product development

Milan, Italy- (WEBSITE ANNOUNCEMENT) –  Deenova, announced today that following its unprecedented European market expansion and increasing new customer adoption, and to sustain its continuous new product developments, Deenova recently appointed Marco D’Incà as Pre-Sales, Solution Design and New Product Development Manager.

Marco D’Incà brings with him 20 years of expertise in the hospital pharmacy automation and intralogistics field, with increasing responsibilities in companies such as e Sinteco e Ferretto Group.

“I am thrilled to join Deenova, to further contribute to its International success.” said Marco D’Incà, “Deenova has demonstrated to be the raising star in the field of pharmacy automation with unique and unmatched solutions aimed at improving patient safety, quality of care and delivering strong financial benefits to healthcare institutions”.

After a long-established leadership on the Italian and French hospital pharmacy automation markets, Deenova has for the last 2 years benefited from a fast internationalization with successful market entries in countries such as United Kingdom, Germany, Spain, Malta and Poland with many other projects still to be announced. In addition the company recently announced the unveiling of three new innovative additions to its award winning D3 product line of mechatronic solutions, in conjunction with the 26th Congress of the European Association of Hospital Pharmacists, in Vienna.

Christophe JaffuelDeenova Chief Commercial Officer, stated: “We know Marco for many years as he is one of the pioneers in this industry. His strong technical expertise both in software and automation product development coupled with his international customer exposure are a great asset for Deenova in this period of unprecedented market expansion.”

About Deenova

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

 

News 14/03/2022

Deenova Launches New Product Line @ EAHP: A Glimpse into Pharmacy Automation’s Future

MILAN–(BUSINESS WIRE)–Deenova today announced the unveiling of three new innovative additions to its award winning D3 product line of mechatronic solutions, in conjunction with the 26th Congress of the European Association of Hospital Pharmacists, in Vienna, Austria, March 23 to 25, 2022, at Stand 30, Hall X2.

Gaspar G. De Viedma, Vice Chairman of Deenova Board of Directors stated: “I am very excited to personally attend this launch, after a few years absence from EAHP for known personal reasons and then Covid-19. I really look forward to reconnect with the European Pharmacists thought leaders in Vienna, and witness first-hand the progress and success that Deenova has achieved in last 2 years.”

AIDE-Cut is one of three new Deenova’s latest modular mechatronic solutions for the repackaging of oral solid medications in unit doses. It offers many possible configurations such as options mono or multi reference, typical or atypical blister format, bulk medications or for the different model of collecting the crated unit doses (in pass boxes, carnet, unit dose rolls, etc).

AIDE-Pack is Deenova’s new solution for the repackaging of all forms of medications (Oral and non Oral) in unit dose format. Each unit dose is identified by a Datamatrix code, summarizing the main characteristics of the medication: a unique serialization number, medication code, expiration and batch.

AIDE-Pick is Deenova D3 series solution developed to fit the needs of the centralized therapy preparation in sub-acute and/or multi-site Healthcare Facilities,

AIDE-Pick stores unit doses created by ACCED, AIDE-Cut, AIDE-Pack, or ALL-IN-1 unique mechatronic solutions.

Christophe Jaffuel, Deenova Chief Commercial Officer, added: “These new D3 additions of AIDE-Pick, AIDE-Cut, AIDE-Pack not only enhances Deenova long established solutions like D3 ACCED and ASTUS, but it also complements Deenova flagship solutions D1 All-In-1 Robot, D1 All-In-1 Station, D1 All-In-1 Trolley, and Orbit in an exclusive, innovative, and integrated approach to Pharmacy Automation.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 10/03/2022

Deenova receives the ISO 27001, Information Security Management System Certification

Milan, Italy- (WEBSITE ANNOUNCEMENT) –  Deenova, announced today that in addition to the already obtained SA8000, ISO9001, ISO13485, ISO14001 and ISO45001 Certifications, last December Deenova also received the ISO/IEC 27001:2013 Information Security Management System certification after successfully completing the requirements and obtaining official accreditation by RINA , the authorized certification services.

Marco Spelta, Chief Information Officer at Deenova, stated: “Meeting the customer requests, ensuring the highest standards of security and quality, is the most important focus for us, so we follow the best practices certified by ISO/IEC 27001:2013: the international standard for an information security management system.”

ISO/IEC 27001 Information Security Management System certification is the leading international standard focused on information security, published by the International Organization for Standardization (ISO), in partnership with the International Electrotechnical Commission (IEC). It sets out the specification for an information security management system (ISMS).

The information security management system standard’s best-practice approach helps organisations manage their information security by addressing people, processes and technology.

RINA is a multinational company that helps clients build strong, successful businesses, with 160 years of experience across a wide range of industries. RINA Certification services provide an independent guarantee of compliance with associated regulatory standards, in order to support enterprises across all aspects of projects, operations, logistics and legislation.

ABOUT DEENOVA

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova‘s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 28/02/2022

Deenova Continues its Sweep of 2022 French Market with Wins at UGECAM and Tourcoing

MILAN–(BUSINESS WIRE)–Deenova announced today it recently won 2 new contract awards for 4 of its award winning mechatronic ACCED robots, first at UGECAM, the leading private non-profit hospital company in France, and additionally Deenova existing customer Centre Hospitalier de Tourcoing.

Loïc Bessin, Managing Director of  Deenova in France stated: “It is self-evident proof of Deenova continued market momentum since 2019 to be able to combine net new business contracts at premier hospital groups like UGECAM, with additional purchases of mechatronic robots by previous Deenova customers such as Centre Hospitalier de Tourcoing, clearly showing a high level of continued satisfaction with our automation solutions amongst our existing customer base.”

UGECAM Alsace is a regional health operator of 16 hospitals for private, not-for-profit, network of health care establishments, spread over the areas of Bas-Rhin and Haut-Rhin. Its range of care is diversified and mainly covers follow-up care and functional rehabilitation. UGECAM Alsace establishments are recognized for their treatment of neurological, cardiovascular, respiratory, nutritional, endocrine, trauma, orthopedic, psychiatric and geriatric pathologies, part of the UGECAM GROUP which has 225 health and medico-social establishments with excellent expertise in specialized fields: severe burns, childhood obesity, cranial and orthopedic injuries, spinal cord pathologies, amputations. With more than 1 billion turnover, it is the leading private non-profit hospital company in France.

Centre Hospitalier de Tourcoing is a regional hospital with 780 beds, located in the northeast of the The European Metropolis of Lille, near the Belgian border, and a group member of the GHT Lille Métropole Flandre Intérieure. It serves an area of 230 municipalities, with a population of 1.5 million inhabitants, and more than 2000 professionals working together to provide patient care.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 15/02/2022

DEENOVA APPOINTS ANDREW LYON AS UK COMMERCIAL DIRECTOR

Milan, Italy- (WEBSITE ANNOUNCEMENT) –  Deenova, announced today that following its successful market entry in UK with the 15 year contract award for the hospital pharmacy at the  University Hospitals of Leicester NHS Trust, and to consolidate its commercial operations, Deenova appointed Andrew Lyon as UK Commercial Director.

Andrew Lyon brings with him more than 20 years of commercial leadership and position in companies such as EksoBionics, Omnicell, Medtrade and Bard(Now BD).

Andrew Lyon stated “I’m delighted that Deenova is investing in the UK market. Unit dose technology represents a pivotal moment for medication management within the NHS, offering great opportunity for improvement in patient safety, reductions in waste and minimising the burden on nurses, enabling them to focus more on the patient. This comes at a time when the NHS is under immense pressure, so I’m very proud to be able to contribute to such an important mission.”

“I am excited to have Andy joining our team to lead our commercial activities in the UK”, declared Christophe Jaffuel, Chief commercial Officer of Deenova. “Deenova successful entry in the UK  last year with the 15 year service contract at the  University Hospitals of Leicester, the 4th largest NHS trust in UK, shows the potential  of our solutions in this Market, and I am confident that Andy will be successful in his new role.”

In August 2021 the company reported it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market.

Deenova solutions benefits were evidenced by the report issued by the East Midlands Academic Health Science Network (AHSN) undertaking an 18 month evaluation. The published results included: 25% reduction in the consumption (and costs) of medicines; 40% reduction in the number of items held in the ward stock cupboard, 60% reduction in medicines wastage, and a reduction in missed doses due to medicine not available on wards from 10% to 1.2%, amongst other patient safety and economic benefits.

ABOUT DEENOVA

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova‘s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 15/02/2022

Deenova Wins UNIHA Largest Ever Pharmacy Automation Public Tender Award in France

MILAN–(BUSINESS WIRE)–Deenova announced today it exclusively won Lot # 2 (the largest and most comprehensive ever) UNIHA Tender for Pharmacy Automation for the next 4 years, beating all of its competitors in the market.

Loïc Bessin, Managing Director of Deenova in France stated: “It is indeed a testament to the teamwork at Deenova to transform the past non-exclusive UniHA relationship to an exclusive contract award that adds all of Deenova established and newly developed solutions to the UniHA portfolio for 1000+ hospitals in France.”

Christophe Jaffuel, Deenova Chief Commercial Officer, stated: “This exclusive UniHA award not only renews UniHA past commitment since 2017 to Deenova long established solutions like D3 ACCED and ASTUS, but it also exclusively adds Deenova flagship solutions D1 All-In-1 Robot, All-In-1 Station, All-In-1-Trolley, and D8 Orbit all launched in 2020, as well as a 2022 newly developed D3 solutions such as AIDE Pick, AIDE Cut and AIDE Pack for UniHA hospitals.”

UniHA, the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers created in 2005 by the hospital staff themselves (32 CHU and 20 CH). As of 2022, 1.065 hospitals have joined the UniHA cooperative, with 115 GHT having conducted € 5.6 billion in group purchases in 2021. UniHA is one of the main European buyers in the field of health and one of the first national buyers, all sectors of activity combined. The essential challenge: to provide citizens with the best treatments available, to provide high-quality hospital services and to preserve equal access to care.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.

Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

News 02/02/2022

DEENOVA APPOINTS ANDREA PIRACCINI AS GENERAL MANAGER

Milan, Italy- (WEBSITE ANNOUNCEMENT) –  Deenova, announced today that following its record-breaking market momentum and European expansion, and within the scope of consolidating its operations and management structure in order to accompany the unprecedented growth, Deenova’s Board of Directors has appointed Andrea Piraccini as General Manager.

Andrea Piraccini, who had recently joined Deenova in August 2021 as CFO and HR Director, is an experienced leader in the field of Automation and logistics and brings with him more than 20 years of executive management  positions in companies such as Ferretto GroupSystem LogisticsSystem Ceramics, SACMI.

Deenova is going through a major transformation driven by a fast expanding market penetration combined with business diversification and start of activities in new market segments” said Andrea “I look forward to building on the solid foundation established by Deenova’s leadership team until now, as we continue our focus on delivering meaningful value to healthcare providers and increased safety for patients”.

ABOUT DEENOVA

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

 

Contacts at Deenova:

Christophe Jaffuel, Martina Buccianti
[email protected]; +39 0523 785311

 

News 31/01/2022

Deenova futuristic solutions for therapy safety at Marienhospital Gelsenkirchen

St. Augustinus Group published, in its company magazine, an interview with Anette Woermann, Director of Pharmacy at Marienhospital Gelsenkirchen, describing the benefits of the ‘Next Level’ project.

Read the original article

Future-oriented solution for medicines therapy safety
Closed Loop Medication Management

The Closed Loop Medication Management (CLMM) process with electronic prescribing, pharmaceutical validation and unit-dose supply is considered by experts to be the gold standard for solving procedural problems in medications supply. The Marienhospital Gelsenkirchen will in future – as the first company nationwide – rely on a partnership with the Italian company Deenova. And thus on future-oriented solutions to ensure even greater patient safety in medicine therapy. Closed loop medication management is to be successively implemented at all six hospital locations belonging to the St. Augustinus service network.

The Italian company Deenova is the leading provider in the field of combined mechatronic (robotics and automation) solutions for closed loop medications and RFID-based medical devices traceability in healthcare.

Anette Woermann, chief pharmacist of the Marienhospital Gelsenkirchen, describes the advantages of the new system. 

What do the readers of this publication mean by the term Closed Loop Medication Management?

Anette Woermann: Closed Loop Medication Management is a system for optimising the entire medication process – from prescription to administration. With CLMM we want to enhance the already very high level of medication safety at the Marienhospital Gelsenkirchen. Currently, medication is checked by the pharmacist on admission. Digitalisation, automation and the resulting better structured cooperation of the various professions in the hospital can systematically further increase medicine therapy safety at all process levels.

What added value do electronic prescribing and pharmaceutical validation bring?

Anette Woermann: There are about 60,000 different medicines on the German market. Digitalisation gives us a tool to make prescribing safer. In the case of allergies, intolerances or other problems, a warning notice and a recommendation of alternative preparations appear to the doctor. In addition, thanks to electronic access, the pharmacist has the opportunity to look at the medications and contribute his medication expertise not only during the admission process, but throughout the entire hospital stay.

How does patient-specific medication work?

Anette Woermann: The electronic prescription is sent to the hospital pharmacy. There, three devices are purchased for the pharmacy, in which individually packaged medicines, so-called unit doses, are produced and provided with a barcode and a lot of information about the medicine. These unit-dose medicines are stored in electronic cabinets on the wards. When the nurses dock their trolley to the automated cabinet before their ward rounds, the medication prescribed in the software is individually filled into a drawer for each patient. Before administration, the bedside nurse scans the patient wristband and the barcode of each medicine. Through this process, each medication administration is checked against the electronic prescription – ensuring that it is the correct medication. The loop is closed by electronically documenting the administration and can thus be digitally tracked at any time.

How will the new system affect staff and patients?

Anette Woermann: In addition to even greater patient safety, CLMM also means an enormous relief for the various professional groups. Doctors will be able to see directly in the system, among other things, medicine dosages that are adapted to the laboratory values. Likewise, all necessary information is immediately available. A considerable relief for the nursing staff results from the fact that the time-consuming preparation of the therapies is taken over by the machine. This gives the staff the capacity to devote themselves even more to the nursing tasks – in other words, to the people. This results in maximum safety for the patient. In hospitals that already work with a unit dose system, the error rate has been reduced to zero. That is also our goal.

What is the concrete advantage of the system offered by Deenova compared to similar, already existing procedures?

Anette Woermann: The fact that the medicines are only collected for the patient at the moment of the medicine round gives the doctor the opportunity to make changes a few minutes beforehand if necessary. That was quite decisive for us. With the classic unit-dose systems, on the other hand, the pharmacy prepares the medicines for the next 24 hours once a day. If the dosage is then changed during the ward round or another medicine is prescribed, this is often only possible with a lot of effort.

When will the system be put into operation at the MHG?

Anette Woermann: The infrastructure will first be prepared by February 2022. This includes a stable WLAN and the implementation of new pharmaceutical software. The first vending machines, in which the medicines are blister-packed into sachets, will arrive in our hospital pharmacy at the end of February 2022. We will then start with a two-month lead time in the pharmacy. The first pilot station is to be launched in May 2022 if possible. If everything works smoothly, the other wards in the MHG will follow successively, and then also all six hospitals affiliated to the service network.

You visited some hospitals in Italy that are already equipped with this system. What impressions did you gain there?

Anette Woermann: I looked at the system in Bergamo, Vimercate and Piacenza under everyday conditions and I am totally enthusiastic. Everything worked smoothly, and not only that. Special solutions have been developed for many special cases that occur in the wards. Many questions have already been thought out. Concepts were developed to cover many special features that simply exist in our multi-faceted company.

WHAT IS CLOSED LOOP?

The Closed Loop system consists of four quadrants. The key factor here is Digitalisation from the first to the last step, with constant safety comparison with the quality indicators.

  1. electronic admission and prescription
  2. pharmacist can also look at the medication during the patient’s stay in hospital if necessary
  3. delivery of medicines tailored to the patient’s individual needs
  4. safe patient administration thanks to individual barcode